Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study

[1]  Meinhard Kieser,et al.  Adaptive designs for single‐arm phase II trials in oncology , 2012, Pharmaceutical statistics.

[2]  A. Schneeweiss,et al.  Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. , 2010, International journal of radiation oncology, biology, physics.

[3]  A. Schneeweiss,et al.  Helical Tomotherapy as a New Treatment Technique for Whole Abdominal Irradiation , 2008, Strahlentherapie und Onkologie.

[4]  A. Schneeweiss,et al.  Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) – Pilot trial of a phase I/II study: study protocol , 2007, BMC Cancer.

[5]  W. Gregory,et al.  Long‐term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age‐matched normal population , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[6]  D. Bodurka,et al.  Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation , 2004, Bone Marrow Transplantation.

[7]  Werner De Gersem,et al.  Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. , 2003, International journal of radiation oncology, biology, physics.

[8]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Alvarez,et al.  Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Bast,et al.  Progress in the management of gynecologic cancer: consensus summary statement. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Mcguire.  Current status of taxane and platinum-based chemotherapy in ovarian cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Sorbe.  Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment , 2003, International Journal of Gynecologic Cancer.

[13]  C. Tropé,et al.  A Systematic Overview of Radiation Therapy Effects in Ovarian Cancer , 2003, Acta oncologica.

[14]  A. Oza,et al.  Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. , 2002, International journal of radiation oncology, biology, physics.

[15]  W. Schlegel,et al.  Inverse planning and intensity-modulated radiotherapy in patients with prostate cancer. , 2002, Frontiers of radiation therapy and oncology.

[16]  B. Erickson,et al.  High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. , 2001, International journal of radiation oncology, biology, physics.

[17]  Linda Hong,et al.  IMRT of large fields: whole-abdomen irradiation. , 2001, International journal of radiation oncology, biology, physics.

[18]  B. Nilsson,et al.  Is there place for radiotherapy in the treatment of advanced ovarian cancer? , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  C. Dalrymple,et al.  Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. , 1999, Gynecologic oncology.

[20]  E. Petru,et al.  The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. , 1999, Gynecologic oncology.

[21]  H. Stettner,et al.  Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. , 1999, Gynecologic oncology.

[22]  A. Fyles,et al.  A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II, and III ovarian cancer. , 1998, International journal of radiation oncology, biology, physics.

[23]  W. Gregory,et al.  A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  B. Duclos,et al.  Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission , 1994, Cancer.

[25]  J O Deasy,et al.  Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. , 1993, Medical physics.

[26]  G. Thomas.  Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? , 1993, Gynecologic oncology.

[27]  G. Thomas,et al.  Integrating radiation therapy into the management of ovarian cancer , 1993, Cancer.

[28]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[29]  W. Sause,et al.  Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Mauro,et al.  Nonoperative management of peripancreatic arterial aneurysms. A 10-year experience. , 1987, Annals of surgery.

[31]  A. Dembo.  Abdominopelvic radiotherapy in ovarian cancer. A 10‐year experience , 1985, Cancer.

[32]  L. Delclos,et al.  Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. , 1975, National Cancer Institute monograph.

[33]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. Whelan,et al.  Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. , 1992, International journal of radiation oncology, biology, physics.

[35]  A. Fyles,et al.  Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. , 1992, International journal of radiation oncology, biology, physics.

[36]  A. Dembo.  Epithelial ovarian cancer: the role of radiotherapy. , 1992, International journal of radiation oncology, biology, physics.